Teladoc Health (NYSE:TDOC) Stock Gets Price Target Bump from Stifel Nicolaus

Key Points

• Stifel Nicolaus raised Teladoc’s price target from $5.50 to $6.50 but maintained a “hold” rating, implying approximately 5.4% downside from the prior close.
• Analyst sentiment remains mixed but averages to “Hold”: five analysts rate the stock a Buy, eleven a Hold, and one a Sell, with an average price target of $7.57.
• Teladoc’s latest quarter beat expectations, reporting revenue of $605.1 million and a loss of $0.15 per share, though revenue declined 3.4% year over year and the company remains unprofitable.

Teladoc Health (NYSE:TDOC - Get Free Report) had its price target upped by stock analysts at Stifel Nicolaus from $5.50 to $6.50 in a research note issued on Thursday, Benzinga reports. The firm currently has a "hold" rating on the health services provider's stock. Stifel Nicolaus's price target points to a potential downside of 5.41% from the company's previous close.

Other equities research analysts have also recently issued reports about the company. Bank of America increased their target price on Teladoc Health from $9.00 to $10.50 and gave the stock a "buy" rating in a research note on Tuesday, July 7th. Needham & Company LLC reaffirmed a "hold" rating on shares of Teladoc Health in a research report on Thursday. Citigroup dropped their price target on shares of Teladoc Health from $11.00 to $7.50 and set a "neutral" rating on the stock in a research note on Monday, August 3rd. Weiss Ratings reiterated a "sell (d-)" rating on shares of Teladoc Health in a research note on Wednesday, August 19th. Finally, Canaccord Genuity Group cut their price objective on shares of Teladoc Health from $11.00 to $10.00 and set a "buy" rating on the stock in a research report on Thursday, July 30th. Five research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $7.57.

Teladoc Health Stock Up 6.5%

Shares of TDOC opened at $6.87 on Thursday. The stock has a market cap of $1.25 billion, a P/E ratio of -6.94 and a beta of 2.14. The business's 50 day moving average price is $6.15 and its 200-day moving average price is $6.46. Teladoc Health has a 52 week low of $4.40 and a 52 week high of $9.89.

Teladoc Health (NYSE:TDOC - Get Free Report) last posted its quarterly earnings data on Wednesday, October 28th. The health services provider reported ($0.15) earnings per share for the quarter, beating analysts' consensus estimates of ($0.22) by $0.07. Teladoc Health had a negative return on equity of 12.15% and a negative net margin of 7.13%. The company had revenue of $605.10 million during the quarter, compared to analyst estimates of $588.14 million. The firm's revenue for the quarter was down 3.4% on a year-over-year basis. During the same quarter last year, the company earned ($0.28) EPS. On average, equities analysts anticipate that Teladoc Health will post -0.92 EPS for the current year.

Insider Transactions at Teladoc Health

In related news, CEO Charles III sold 17,805 shares of the company's stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $6.10, for a total value of $108,610.50. Following the transaction, the chief executive officer directly owned 465,535 shares of the company's stock, valued at approximately $2,839,763.50. This represents a 3.68% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 0.70% of the company's stock.

Institutional Trading of Teladoc Health

A number of institutional investors and hedge funds have recently modified their holdings of the business. Renaissance Technologies LLC raised its stake in Teladoc Health by 1.3% during the 1st quarter. Renaissance Technologies LLC now owns 8,085,542 shares of the health services provider's stock valued at $44,066,000 after buying an additional 107,400 shares during the last quarter. Monaco Asset Management SAM purchased a new position in shares of Teladoc Health in the 2nd quarter worth $26,864,000. Pale Fire Capital SE boosted its stake in shares of Teladoc Health by 74.8% in the 1st quarter. Pale Fire Capital SE now owns 3,398,491 shares of the health services provider's stock worth $18,522,000 after buying an additional 1,454,288 shares during the last quarter. Quantinno Capital Management LP boosted its stake in shares of Teladoc Health by 128.0% in the 1st quarter. Quantinno Capital Management LP now owns 2,621,378 shares of the health services provider's stock worth $14,287,000 after buying an additional 1,471,631 shares during the last quarter. Finally, Counterpoint Mutual Funds LLC grew its holdings in shares of Teladoc Health by 1,017.4% in the third quarter. Counterpoint Mutual Funds LLC now owns 1,650,165 shares of the health services provider's stock worth $9,571,000 after acquiring an additional 1,502,488 shares during the period. Institutional investors own 76.82% of the company's stock.

More Teladoc Health News

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Teladoc reported third-quarter revenue of $605.1 million, exceeding analyst expectations of approximately $588 million. Its adjusted loss of $0.15 per share was also narrower than the expected $0.23 loss, producing earnings and revenue surprises of roughly 35% and 3%, respectively. Teladoc Reports Q3 Loss, Beats Revenue Estimates
• Positive Sentiment: The results showed year-over-year improvement in the loss, with the quarterly loss per share improving from $0.21–$0.28 a year earlier to $0.15. BetterHelp insurance revenue reached $32 million, providing a potential growth avenue for the struggling mental-health business. Teladoc: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: From a technical perspective, TDOC shares crossed above their 200-day moving average, a development that can attract momentum-oriented investors and signal improving market sentiment after a prolonged decline. Teladoc Shares Cross Above 200-Day Moving Average
• Neutral Sentiment: Management forecast fourth-quarter revenue of $569 million to $615 million, or approximately $592 million at the midpoint. The range provides visibility into the near-term outlook, although the midpoint is slightly below consensus expectations. Teladoc Expects Q4 Revenue Range
• Negative Sentiment: Third-quarter revenue declined 3.4% year over year, showing that Teladoc remains in a low-growth environment despite beating estimates. The company also continued to report a net loss and negative profitability metrics. Teladoc Third-Quarter Earnings Results
• Negative Sentiment: The fourth-quarter revenue outlook remains subdued, reinforcing concerns that BetterHelp and the broader virtual-care business may need more time to return to sustained growth. Teladoc Q3 2026 Earnings Call Transcript

About Teladoc Health

Teladoc Health, Inc provides virtual healthcare services and technology designed to connect patients with medical professionals remotely. Through its digital platforms, the company supports a range of healthcare needs, including general medical consultations, mental health services, specialty care, and ongoing management of chronic conditions.

Its offerings include telehealth visits with physicians and other licensed providers, behavioral health services through BetterHelp, and chronic care programs that use digital tools and clinical support to help people manage conditions such as diabetes and hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.